CardioHeal is designed as an injectable hydrogel for minimally invasive delivery of ADSC-derived exosomes to promote cardiac regeneration following myocardial infarction.
ADSC
Exosome payload
ROS
Oxidative stress control
LVEF
Functional endpoint
Clinical Problem
Myocardial infarction leaves oxygen-starved tissue, oxidative stress, cardiomyocyte death, inflammation, and fibrosis. Conventional approaches can restore blood flow, but the damaged infarct zone still needs localized regenerative support.
Mechanism
The hydrogel acts as a minimally invasive depot for ADSC-derived exosomes and supportive biomaterial cues. It localizes healing signals near the infarct zone instead of relying on diffuse systemic delivery.
Material Platform
The platform draws from thermo-responsive and oxygen-releasing antioxidant biomaterials, elastomeric cardiac patch research, and hydrogel systems engineered for tissue-compatible mechanical support.
Proof & Translation
The CardioHeal pamphlet highlights preclinical rat ischemia-reperfusion studies demonstrating enhanced cardiac regeneration, reduced scar formation, and significant improvement in left ventricular ejection fraction.
Hemostat Regenmedica Source
The CardioHeal pamphlet frames the product around four clear properties: injectable delivery, ROS attenuation, mechanical support, and regenerative activity through ADSC-derived exosomes.
Post-MI cardiac repair
CardioHeal targets damaged heart tissue after myocardial infarction with localized regenerative hydrogel delivery.
01
A minimally invasive hydrogel is positioned near the damaged cardiac tissue.
02
The gel forms a supportive depot that keeps regenerative signals concentrated at the injury site.
03
Exosomes, oxygen support, and antioxidant cues help reduce fibrosis while encouraging angiogenesis and repair.
Translation Status
Current Status: Porcine preclinical studies